AbbVie (ABBV)
(Delayed Data from NYSE)
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.53 -0.02 (-0.01%) 8:56 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.53 -0.02 (-0.01%) 8:56 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
AbbVie (ABBV) Beats Earnings and Revenue in Q1
by Zacks Equity Research
AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.
5 Fantastic Earnings Charts
by Tracey Ryniec
Tracey brings you the companies with the best earnings charts each week.
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
by Zacks Equity Research
Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
by Zacks Equity Research
Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)
What's in Store for AbbVie (ABBV) this Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.
What's in Store for Biogen (BIIB) this Earnings Season?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
Repros' Proellex Continues to be Under Partial Clinical Hold
by Zacks Equity Research
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.
AbbVie's Elagolix Meets Primary Endpoint in Phase II Study
by Zacks Equity Research
AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.
AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
by Zacks Equity Research
Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.
Novartis (NVS) Reports Positive Data on Biosimilar Humira
by Zacks Equity Research
Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.
Inovio (INO): What's in the Cards this Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.
BioDelivery (BDSI): What's in Store this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.
J&J Presents Positive Phase III Data on Psoriasis Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Pricing to Remain Pharma Headline Risk in 2017
by Arpita Dutt
Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.